FDA Rejects uniQure’s AMT-130 Gene Therapy Approval Plan, Sending QURE Stock Plunging

Key Takeaways

• Shares of uniQure plummeted approximately 45% following the FDA’s dismissal of the company’s planned regulatory route for AMT-130.

• Federal regulators determined that initial and intermediate-phase clinical trial results failed to provide adequate backing for market authorization.

• The agency advised conducting a fresh randomized, controlled clinical investigation prior to submitting any approval request.

• The biotech firm intends to schedule another regulatory consultation during the second quarter of 2026 for Phase III trial planning.

• This regulatory hurdle may significantly extend development schedules for the Huntington’s disease treatment candidate.

Shares of uniQure (QURE) experienced a dramatic selloff following news that the U.S. Food and Drug Administration turned down the company’s proposed regulatory strategy for its investigational gene therapy AMT-130. The announcement sent the stock tumbling during early market hours.

uniQure N.V., QURE

Federal regulators concluded that evidence gathered from Phase I/II clinical investigations was inadequate to justify filing for marketing authorization. The agency determined that relying on comparisons with external control groups failed to satisfy standards for demonstrating treatment effectiveness.

This guidance emerged from a Type A consultation conducted on January 30. Official meeting documentation verified the agency’s stance regarding the proposed submission approach.

The FDA suggested that uniQure initiate a prospective, randomized, double-blind clinical investigation. The recommended protocol would incorporate a sham surgical procedure control arm to collect robust comparative data.

uniQure announced plans to maintain ongoing dialogue with federal regulators concerning the advancement of AMT-130. The biotechnology company aims to schedule a Type B consultation during Q2 2026 to address future clinical trial architecture.

Impact on Development Schedule and Regulatory Strategy

This regulatory decision constitutes a significant postponement of the firm’s development schedule. uniQure had originally targeted submitting a marketing application for AMT-130 during early 2026.

The investigational gene therapy targets Huntington’s disease. This hereditary neurological condition results in gradual deterioration of neurons within the brain.

No approved therapies currently exist that halt disease progression. uniQure had anticipated that early and intermediate-phase clinical evidence would be sufficient for regulatory submission.

Earlier study outcomes demonstrated reduced disease progression across a three-year observation period based on established clinical assessment tools. Notwithstanding these observations, the FDA indicated that additional controlled evidence is necessary.

Conducting a fresh randomized clinical investigation will demand considerable additional time and financial investment. This requirement will likely postpone any prospective regulatory filing and commercial launch.

Future Plans and Management’s Perspective

uniQure indicated it will maintain active communication with regulatory authorities to establish the optimal path forward. Company leadership emphasized that future conversations will center on Phase III trial architecture and specific regulatory requirements.

Management expressed confidence that accumulated clinical evidence justifies ongoing regulatory discussions. The company also highlighted the sustained therapeutic effects documented in previous clinical studies.

Industry observers pointed out that executing a new controlled clinical trial will substantially extend the development timeline. Significant additional trial expenditures may be necessary before pursuing regulatory approval.

The biotechnology firm plans to arrange a subsequent regulatory meeting with the FDA during Q2 2026. These discussions are anticipated to address potential routes for progressing AMT-130 toward an eventual marketing application.

uniQure reaffirmed its dedication to advancing this gene therapy candidate notwithstanding the regulatory obstacle. Additional information is anticipated following further regulatory consultations scheduled for later in 2026.

The post FDA Rejects uniQure’s AMT-130 Gene Therapy Approval Plan, Sending QURE Stock Plunging appeared first on Blockonomi.